This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
In November 2023, the United States Food and Drug Administration (FDA) approved enzalutamide, with or without concurrent leuprolide therapy, for non-metastatic hormone-sensitive prostate cancer (M0 ...
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of ...
Matthew Cooperberg hosts a discussion with Jesse McKenney and Cornelia Ding about research on prostate cancer grading, presented in a paper proposing a new definition of adverse pathology. Dr.
This review, published in Nature Urology Reviews, explores a relatively less common but dangerous entity of metastatic non-muscle-invasive bladder cancer (mNMIBC). This is a challenging condition ...
European Continence Strategy Targets Escalating Costs and Inequalities in Incontinence Care - Philip van Kerrebroeck ...
Urinary incontinence (UI), the complaint of involuntary leakage of urine, has a substantial impact on the quality of life of older adults. Most UI research is driven by researchers and lacks the ...
Historically, Asia had a lower prostate cancer (PCa) incidence and mortality compared with Western countries, but the gap is narrowing. Paradoxically, Asians have been reported to present with more ...
To evaluate a cancer detecting artificial intelligence (AI) algorithm on serial biopsies in patients with prostate cancer on active surveillance (AS). A total of 180 patients in the Prostate Cancer ...
Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, ...